Condition (MeSH)
Hereditary Breast and Ovarian Cancer Syndrome
ClinicalTrials.gov lists 60 trials for Hereditary Breast and Ovarian Cancer Syndrome or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
60 of the 60 trials are tagged with Hereditary Breast and Ovarian Cancer Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Hereditary Breast and Ovarian Cancer Syndrome trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 1 |
| 2023 | 3 |
| 2021 | 2 |
| 2020 | 6 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 10 |
| 2016 | 6 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hereditary Breast and Ovarian Cancer Syndrome trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 28 |
| Observational | 19 |
How many Hereditary Breast and Ovarian Cancer Syndrome trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 9 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 6 |
| Completed | 29 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hereditary Breast and Ovarian Cancer Syndrome trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Gynecologic Oncology Group | 2 |
| Sheba Medical Center | 2 |
| Aspira Women's Health | 1 |
Which drugs are being tested for Hereditary Breast and Ovarian Cancer Syndrome? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Veliparib | 2 |
| Prexasertib | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 2 |
| Blood collection | 2 |
| Letrozol (Femara, Novartis) | 1 |
| acid Zoledronic | 1 |
| Supportive Care | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hereditary Breast and Ovarian Cancer Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 11 | 1 |
| Fever | 11 | 1 |
| Febrile neutropenia | 10 | 1 |
| Neutrophil count decreased | 9 | 1 |
| Vomiting | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hereditary Breast and Ovarian Cancer Syndrome? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial. | Public health genomics | 2024 | Yes |
| Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial. | JAMA network open | 2022 | Yes |
| Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. | Gynecologic oncology | 2022 | Yes |
| Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. | Breast cancer (Tokyo, Japan) | 2021 | Yes |
| Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors. | Journal of genetic counseling | 2021 | Yes |
Showing 5 of 20 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hereditary breast and/or ovarian cancer syndrome | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Hereditary breast and/or ovarian cancer syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Hereditary breast and/or ovarian cancer syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hereditary breast and/or ovarian cancer syndrome | 145 | Exact | Orphadata Science knowledge files, Product 1 |
| Hereditary breast and/or ovarian cancer syndrome | 145 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.